Alina Galata
Mary Gates Research Scholar
Autumn 2025
Project
HIV-2 Susceptibility to HIV-2 Broadly-Neutralizing Antibodies
This project aims to determine whether or not broadly neutralizing antibodies isolated from HIV-1 patients are effective at preventing and treating HIV-2. In order to determine the susceptibility of HIV-2 to the bNAbs teropavimab and zinlirvimab, I will be constructing HIV-2 clones with envelope protein genes that have been isolated from patients, and performing assays in order to quantify the ability of the HIV-2 viruses to kill cells when the bNAbs are present in varying concentrations. From these assays, IC50 graphs will be constructed in order to quantify the effectiveness of the bNAbs on preventing HIV-2 infection of naive cells. We expect that they will not be very effective in preventing infection of the cells, as the envelope proteins that the bNAbs target are very different in sequence between HIV-1 and HIV-2. However, it is important to determine whether or not these bNAbs are a viable prevention and treatment option for HIV-2, as there are very few HIV-2 treatments approved by the FDA, and many of the HIV-1 treatments that are available are ineffective against HIV-2, due to the intrinsic resistance HIV-2 has against these drugs. If the bNAbs are a useful treatment option for HIV-2, it will be one of a very few select drugs that can treat it, and if they are not, then at least we know this, and do not have to put patients through the treatments, which can involve many side effects, not knowing whether or not the treatment is effective.